Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Cancer J. 2019 Nov-Dec;25(6):394–400. doi: 10.1097/PPO.0000000000000414

Table 1.

Isoform Inhibition Profiles of PI3Kδ Inhibitors that are FDA Approved or in Advanced Clinical Development (IC50 values, nM)

Drug Name p110α p110β p110δ p110γ
Idelalisib9 820 565 2.5 89
Duvelisib26 1602 85 2.5 27
Copanlisib51 0.5 3.7 0.7 6.4
Umbralisib37 >10000 1116 22 1065
Parsaclisib43 >20000 >20000 1 >20000
ME-40145 22867 30 0.6 713